Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.
On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S. until the end of 2022.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Aktie
355,40 €
1,25 %
Die Community zeigt großes Interesse an Amgen Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Ein negatives Potenzial von -5.46% für Amgen Inc., trotz eines Kursziels von 336 €, das niedriger als 355.4 € ist.
